We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Fecal Immunochemical Test Effective for Annual Colon Cancer Screening

By LabMedica International staff writers
Posted on 10 Feb 2016
The fecal immunochemical test (FIT) is highly sensitive for detecting colorectal cancer, and adherence to annual follow-up screening among initial participants is high, making the noninvasive test feasible and effective for annual colorectal cancer screening programs. More...


Colorectal cancer (CRC) is the second leading cause of cancer death in the USA. Evidence shows that highly sensitive guaiac-based fecal occult blood tests (FOBT), which are recommended for annual screening of average risk patients between the ages of 50 and 75, can reduce morbidity and mortality from colorectal cancer. FIT has higher detection rates for CRC and advanced adenomas than FOBT, but little is known about how well FIT works over several rounds of annual screening.

Scientists working for Kaiser Permanente (Oakland, CA, USA) and their colleagues carried out a retrospective cohort study and collected data on 323,349 health plan members aged 50 to 70 years. The members were on their FIT mailing date in 2007 or 2008 and had completed the first round of FIT and were followed for up to four screening rounds. Screening participation included an FIT positivity, equal to or greater than 20 µg of hemoglobin/g, which has positive predictive values for adenoma and CRC, and FIT sensitivity for detecting CRC obtained from Kaiser Permanente electronic databases and cancer registries.

Of the patients invited for screening, 48.2% participated in round one. Of those who remained eligible, 75.3% to 86.1% participated in subsequent rounds. Median follow-up was 4.0 years, and 32% of first round participants crossed over to endoscopy over four screening rounds and 7.0% were due to a positive FIT result. The FIT positivity rate of 5.0% and positive predictive values (adenoma, 51.5%; CRC, 3.4%) were highest in the first round.

Overall, programmatic FIT screening detected 80.4% of patients with CRC diagnosed within one year of testing, including 84.5% in round one and 73.4% to 78.0% in subsequent rounds. The authors concluded that annual FIT screening was associated with high sensitivity for CRC, with high adherence to annual follow-up screening among initial participants. The findings indicate that annual programmatic FIT screening is feasible and effective for population-level CRC screening. The study was published on January 26, 2016, in the journal Annals of Internal Medicine.

Related Links:

Kaiser Permanente



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more

Microbiology

view channel
Image: The SMART-ID Assay delivers broad pathogen detection without the need for culture (Photo courtesy of Scanogen)

Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples

Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.